ArticleMedical microbiology and immunology2014
Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa.
Article in Medical microbiology and immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- The Accuracy of Diagnostic Tests for Lyme Disease in Humans, A Systematic Review and Meta-Analysis of North American Research.PloS one · 2016Pooled it
- Clinical data on symptomatic cutaneous reinfections due to Borrelia burgdorferi sensu lato in Slovenia.Infection · 2026Article
- A novel single-tier serologic test to diagnose all stages of Lyme disease.Journal of clinical microbiology · 2025Article
- Class and isotype of VlsE-specific antibody differentiates Lyme disease stage.Journal of clinical microbiology · 2025Article
- Serologic biomarker discovery for differentiating Lyme disease from diseases with similar clinical symptoms using broad profiling of antibody binding.Frontiers in immunology · 2025Article
- Persistent Anti-Microbiology spectrum · 2021Article
- Comparison of Lyme Disease in the United States and Europe.Emerging infectious diseases · 2021Review
- Laboratory Diagnosis of Lyme Borreliosis.Clinical microbiology reviews · 2021Review
- Under-Detection of Lyme Disease in Canada.Healthcare (Basel, Switzerland) · 2018Article
- A Community Study ofHealthcare (Basel, Switzerland) · 2018Article
- Utility ofBioMed research international · 2018Article
- Evaluation of the C6 Lyme Enzyme Immunoassay for the Diagnosis of Lyme Disease in Children and Adolescents.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
- Review
- Antibody profile to Borrelia burgdorferi in veterinarians from Nuevo León, Mexico, a non-endemic area of this zoonosis.Reumatologia · 2016Article
- Lyme disease: How reliable are serologic results?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
- Lyme neuroborreliosis-epidemiology, diagnosis and management.Nature reviews. Neurology · 2015Review
- Laboratory diagnosis of Lyme disease: advances and challenges.Infectious disease clinics of North America · 2015Review
- C6 Peptide-Based Multiplex Phosphorescence Analysis (PHOSPHAN) for Serologic Confirmation of Lyme Borreliosis.PloS one · 2015Article
- Relevance of chronic lyme disease to family medicine as a complex multidimensional chronic disease construct: a systematic review.International journal of family medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although two-tier testing is standard practice in both the United States and Europe for the serologic diagnosis of Lyme borreliosis (LB), the test kits generally differ. The purpose of this study was to determine if the testing used in the United States will detect LB acquired in Europe and vice versa. Testing was performed on a convenience sample of archived sera from 40 LB patients from Austria and 39 from the United States, using first- and second-tier test kits from both the United States and Europe. The sensitivity of four first-tier tests from Europe and two first-tier tests from the United States was similar. Thus, two-tier testing was compared to the C6 ELISA as the first-tier test, since it is licensed in both the United States and Europe. The sensitivity of C6 two-tier testing with US assays was 9/40 (22.5 % [95 % CI 10.8-38.5 %]) for detection of LB acquired in Europe, and just 20.0 % (95 % CI 2.5-55.6 %) in the ten European patients with neurologic involvement. These results differed significantly from the sensitivity of European C6 two-tier testing that was 70.0 % (95 % CI 53.5-83.4 %) overall (p < 0.001) and 90.0 % (95 % CI 55.5-99.7 %) for the European patients with neurologic manifestations specifically (p = 0.016). In contrast, the sensitivity of European and US C6 two-tier testing was similar for detection of LB acquired in the United States. Two-tier serologic testing with the US test kits may be unsatisfactory for detection of LB acquired in Europe. First-tier testing with an assay such as the C6 ELISA should be considered as a stand-alone diagnostic strategy in such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.